Supplemental Table 1. Patient Characteristics.
| Large-artery atherosclerosis |
Small-artery occlusion (lacunar) |
Acute stroke of other determined etiology |
Stroke of undetermined etiology |
|||||
|---|---|---|---|---|---|---|---|---|
| Prasugrel | Clopidogrel | Prasugrel | Clopidogrel | Prasugrel | Clopidogrel | Prasugrel | Clopidogrel | |
| n = 553 | n = 546 | n = 583 | n = 593 | n = 35 | n = 49 | n = 714 | n = 674 | |
| Age (years), mean ± SD | 62.7 ± 8.8 | 63.1 ± 8.2 | 61.8 ± 8.0 | 62.4 ± 7.8 | 56.9 ± 13.1 | 57.5 ± 11.5 | 61.5 ± 8.8 | 62.3 ± 8.6 |
| Sex (female), n (%) | 115 (20.8) | 117 (21.4) | 105 (18.0) | 106 (17.9) | 4 (11.4) | 8 (16.3) | 162 (22.7) | 180 (26.7) |
| Body weight (kg), mean ± SD | 65.6 ± 10.4 | 65.3 ± 8.9 | 66.0 ± 10.0 | 65.6 ± 9.8 | 68.2 ± 9.4 | 67.1 ± 10.0 | 65.7 ± 11.1 | 65.1 ± 10.1 |
| Body mass index, mean ± SD | 24.5 ± 3.2 | 24.4 ± 2.8 | 24.6 ± 3.2 | 24.4 ± 3.0 | 24.2 ± 2.6 | 24.7 ± 2.9 | 24.5 ± 3.3 | 24.5 ± 3.2 |
| Blood pressure (mmHg), mean ± SD | ||||||||
| Systolic | 133.0 ± 15.6 | 133.8 ± 14.7 | 135.1 ± 13.9 | 135.3 ± 14.4 | 131.9 ± 15.0 | 131.2 ± 16.3 | 134.8 ± 14.3 | 134.7 ± 15.0 |
| Diastolic | 78.3 ± 11.0 | 78.4 ± 11.0 | 81.0 ± 10.7 | 80.4 ± 10.6 | 81.5 ± 10.2 | 77.3 ± 10.9 | 80.1 ± 10.5 | 79.8 ± 10.9 |
| Modified Rankin Scale, n (%) | ||||||||
| Grade 0 | 145 (26.2) | 124 (22.7) | 137 (23.5) | 157 (26.5) | 10 (28.6) | 16 (32.7) | 152 (21.3) | 153 (22.7) |
| Grade 1 | 267 (48.3) | 283 (51.8) | 357 (61.2) | 361 (60.9) | 20 (57.1) | 26 (53.1) | 382 (53.5) | 358 (53.1) |
| Grade 2 | 89 (16.1) | 96 (17.6) | 72 (12.3) | 64 (10.8) | 4 (11.4) | 6 (12.2) | 126 (17.6) | 107 (15.9) |
| Grade 3 | 37 (6.7) | 27 (4.9) | 11 (1.9) | 9 (1.5) | 0 (0.0) | 1 (2.0) | 40 (5.6) | 38 (5.6) |
| Grade 4 | 15 (2.7) | 16 (2.9) | 6 (1.0) | 2 (0.3) | 1 (2.9) | 0 (0.0) | 14 (2.0) | 18 (2.7) |
| History of atherosclerotic disease, n (%) | ||||||||
| Ischemic stroke | 71 (12.8) | 68 (12.5) | 84 (14.4) | 85 (14.3) | 3 (8.6) | 6 (12.2) | 60 (8.4) | 52 (7.7) |
| TIA | 44 (8.0) | 45 (8.2) | 29 (5.0) | 25 (4.2) | 2 (5.7) | 2 (4.1) | 24 (3.4) | 21 (3.1) |
| Complication, n(%) | ||||||||
| Hypertension | 442 (79.9) | 429 (78.6) | 476 (81.6) | 509 (85.8) | 26 (74.3) | 36 (73.5) | 561 (78.6) | 536 (79.5) |
| Dyslipidemia | 405 (73.2) | 405 (74.2) | 377 (64.7) | 405 (68.3) | 22 (62.9) | 31 (63.3) | 492 (68.9) | 464 (68.8) |
| Diabetes mellitus | 195 (35.3) | 196 (35.9) | 186 (31.9) | 203 (34.2) | 7 (20.0) | 12 (24.5) | 223 (31.2) | 225 (33.4) |
| Duration from onset to the study treatment, n(%) | ||||||||
| < 4 weeks | 80 (14.5) | 81 (14.8) | 103 (17.7) | 117 (19.7) | 1 (2.9) | 9 (18.4) | 132 (18.5) | 115 (17.1) |
| ≥ 4 weeks, < 12 weeks | 274 (49.5) | 279 (51.1) | 327 (56.1) | 335 (56.5) | 24 (68.6) | 24 (49.0) | 413 (57.8) | 394 (58.5) |
| ≥ 12 weeks | 199 (36.0) | 186 (34.1) | 153 (26.2) | 141 (23.8) | 10 (28.6) | 16 (32.7) | 169 (23.7) | 165 (24.5) |
| Clopidogrel pretreatment, n (%) | ||||||||
| Yes | 185 (33.5) | 175 (32.1) | 259 (44.4) | 259 (43.7) | 13 (37.1) | 15 (30.6) | 273 (38.2) | 254 (37.7) |
| No | 368 (66.5) | 371 (67.9) | 324 (55.6) | 334 (56.3) | 22 (62.9) | 34 (69.4) | 441 (61.8) | 420 (62.3) |
| Concomitant medication | ||||||||
| PPI | 184 (33.3) | 174 (31.9) | 174 (29.8) | 179 (30.2) | 10 (28.6) | 12 (24.5) | 251 (35.2) | 209 (31.0) |
| Statin | 289 (52.3) | 290 (53.1) | 228 (39.1) | 259 (43.7) | 19 (54.3) | 23 (46.9) | 329 (46.1) | 321 (47.6) |
| ARB | 269 (48.6) | 244 (44.7) | 292 (50.1) | 312 (52.6) | 6 (17.1) | 28 (57.1) | 340 (47.6) | 320 (47.5) |
| Insulin | 20 (3.6) | 22 (4.0) | 18 (3.1) | 20 (3.4) | 0 (0.0) | 0 (0.0) | 22 (3.1) | 14 (2.1) |
ARB = angiotensin II receptor blocker, eGFR = estimated glomerular filtration rate, SD = standard deviation, PPI = proton pump inhibitor, TIA = transient ischemic attack